Palobiofarma, Novartis deal

Palobiofarma granted Novartis exclusive, worldwide rights to develop and commercialize PBF-509. Palobiofarma said the adenosine A2A receptor (ADORA2A) antagonist is entering Phase I testing to treat non-small cell lung cancer (NSCLC). The company also granted Novartis rights to IP related to the role of adenosine in immunotherapy. ...